Erlotinib for advanced hepatocellular carcinoma: A systematic review of phase II/III clinical trials

OBJECTIVES: To evaluate the efficacy and safety of erlotinib for the treatment of advanced hepatocellular carcinoma (HCC). METHODS: A systematic literature search was undertaken in June 2015. Phase II/III trials of erlotinib for the treatment of advanced HCC were included. A descriptive analysis was...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Zong, Yuan, Xu, Gang-Zhu, Xing, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2016
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303794/
https://www.ncbi.nlm.nih.gov/pubmed/27761555
http://dx.doi.org/10.15537/smj.2016.11.16267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303794/
https://www.ncbi.nlm.nih.gov/pubmed/27761555
http://dx.doi.org/10.15537/smj.2016.11.16267

Ejemplares similares